Strated by confocal imaging and flow cytometry. We showed that 10E8-Exo could successfully bind to CHO cell that expresses a trimeric gp140 on its surface. The exosomes loaded with curcumin, a chemical that was shown to kill HIV-infected cells, showed precise killing with the trimeric gp140-expressing CHO cells. In an NCG mouse model that was grafted together with the tumorigenic gp140-CHO cells and created solid tissue tumours intravenously injected 10E8-Exo targeted the ENV-expressing tissues and delivered curcumin to induce a robust suppression of the ENV+ tumour growth with a low toxicity. Results: Our final results demonstrated that engineered exosomes can deliver anti-HIV agents to strong tissues by particularly targeting cells expressing viral env and induce cell killings. Summary/Conclusion: It suggesting that such an approach can be developed for eradicating virusinfected cells in tissue reservoir. Funding: This study was supported by The National Important Research and Development Plan of China (2016YFC1201000), PD-L1/CD274 Proteins Purity & Documentation Nature Science Foundation of Jiangsu Province (BY2015069-02) and National Nature Science Foundation of China (81672020). The funders had no role in study design, information collection and evaluation, decision to publish, or preparation on the manuscript.for the antigenic similarity between OMVs plus the bacterial outer membrane, OMVs have proven to become promising for the improvement of novel vaccines against bacterial pathogens. In this work, we describe the testing of OMVbased vaccine prototypes against Gallibacterium anatis, a Gram-negative pathogen of fantastic veterinary interest. Methods: OMVs had been isolated from a G. anatis hypervesiculating mutant making use of a modified version with the Hydrostatic CD53 Proteins Biological Activity Filtration protocol described by Musante et al. (2014). 120 16-week-old Lohmann-Brown chickens were divided in six groups and immunized twice intramuscularly with unique combinations of buffer (controls), OMVs and chosen recombinant immunogens. Two weeks immediately after second immunization, the effectiveness of your immunization regimes adopted was tested by challenging the animals intraperitoneally with live CFUs from a heterologous G. anatis strain. A single week post-challenge, the animals have been sacrificed and an established lesion score model was made use of during necropsy to evaluate the clinical outcome of infection. Results: Statistical evaluation of your recorded lesion scores showed that the group immunized with G. anatis OMVs presented an average total score of two.95, as opposed to an typical total score of eight.77 inside the control group. The roughly three-fold reduction in total average lesion score observed demonstrates that immunization with G. anatis OMVs is able to properly decrease the morbidity of G. anatis infection in the immunized animals. Summary/Conclusion: Our results show that G. anatis OMVs represent a promising candidate for the improvement of cost-effective vaccination strategies for the prevention of G. anatis infections in a cross-serovar manner. Accordingly, we hypothesize that dose/ response optimization and also the enrichment of G. anatis OMVs with selected immunogens must result in an improvement with the effectiveness of the vaccination regime proposed. Funding: This investigation project is becoming funded by a grant from Huvepharma (https://www.huvepharma. com/).OWP2.11=PS02.In vivo testing of OMV-based vaccine prototypes against Gallibacterium anatis Fabio Antenuccia, Homa Arakb, Jianyang Gaob, Toloe Allahghadryb, Ida Th nerb and Anders Miki BojesencaOWP.